Recombinant Technologies [RTL] is a privately held, development stage company founded by Dr. Sundaram in 1999. RTL's current focus is on developing small molecules to treat Alzheimer's disease. Through multiple SBIR grants from the National Institutes of Health, RTL has successfully tested the 'proof-of-concept' of its one of the three proprietary small molecules.
This molecule is queued for IND-enabling preclinical studies. The company is committed to the development and commercialization of new therapies for Alzheimer's disease and has assembled a team of business and scientific leaders to reach its goals. RTL is currently funded by a combination of private funds and SBIR grants.